Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record.

Treatment of unresectable cholangiocarcinoma using yttrium‐90 microspheres: Results from a pilot study

Open access
Ibrahim, Saad M., Mulcahy, Mary F., Lewandowski, Robert J., Sato, Kent T., Ryu, Robert K., Masterson, Elizabeth J., Newman, Steven B., Benson, Al, Omary, Reed A., Salem, Riad·2008·Cancer

Abstract

BACKGROUND.: The objective of this report was to present data from an open‐label cohort study in which patients with intrahepatic cholangiocarcinoma (ICC) underwent radioembolization with yttrium‐90 (90 Y) microspheres. METHODS.: Twenty‐four patients with histologically proven ICC were treated. The planned target dose was 120 Gray. Patients were stratified according to Eastern Cooperation Oncology Group (ECOG) performance status, tumor morphology (infiltrative vs peripheral), tumor distribution (solitary vs multifocal), and the presence or absence of portal vein thrombosis (PVT). Before and after the procedure, the following variables were assessed: 1) biochemical and clinical toxicity, 2) imaging (computed tomography/magnetic resonance imaging) response according to World Health Organization and European Association for the Study of Liver Disease (EASL) criteria, and 3) median survival after the first treatment using Kaplan‐Meier methodology. RESULTS.: In total, 48 90 Y treatments were administered to hepatic segments or lobes. Fatigue and transient abdominal pain were reported in 18 patients (75%) and 10 patients (42%), respectively. One patient (4%) developed grade 3 bilirubin toxicity. One patient (4%) developed a treatment‐related gastroduodenal ulcer. On imaging follow‐up of 22 patients, tumors demonstrated a partial response in 6 patients (27%), stable disease in 15 patients (68%), and progressive disease in 1 patient (5%). By using EASL guidelines, 17 patients (77%) showed >50% tumor necrosis on imaging follow‐up. Two patients (9%) demonstrated 100% tumor necrosis. The median overall survival for the entire cohort (n = 24) was 14.9 months. The median survival for patients with an ECOG performance status of 0, 1, and 2 was 31.8 months, 6.1 months, and 1 month, respectively (P < .0001); the median survival for patients without and with PVT was 31.8 months and 5.7 months, respectively (P = .0003); and the median survival for patients with peripheral versus periductal‐infiltrative tumors was 31.8 months and 5.7 months, respectively (P = .0005). CONCLUSIONS.: Radioembolization with 90 Y may be a therapeutic option for the treatment of unresectable ICC. Cancer 2008. © 2008 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.23818

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 188

Metadata

Authors
Ibrahim, S. M., Mulcahy, M. F., Lewandowski, R. J., Sato, K. T., Ryu, R. K., Masterson, E. J., Newman, S. B., Benson, A., Omary, R. A., & Salem, R.
Venue
Cancer
Publisher
Wiley
Published
2008-10-03
Volume
113
Issue
8
Pages
2119-2128
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1504363060
Cited by
188
References
0
FWCI
8.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of unresectable cholangiocarcinoma using yttrium‐90 microspheres: Results from a pilot study. https://app.cochat.ai/papers/10.1002/cncr.23818
The paper
Ibrahim, S. M., Mulcahy, M. F., Lewandowski, R. J., Sato, K. T., Ryu, R. K., Masterson, E. J., Newman, S. B., Benson, A., Omary, R. A., & Salem, R. (2008). Treatment of unresectable cholangiocarcinoma using yttrium‐90 microspheres: Results from a pilot study. Cancer. https://doi.org/10.1002/cncr.23818

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.